Coagulopathy is a major cause of morbidity and mortality in patients who have suff ered severe hemorrhage and received massive transfusions. Administration of a fi brinogen concentrate along with red blood cells can quickly restore hemostasis in a clinically relevant animal model.
Severe traumatic injury is frequently associated with hemorrhagic shock necessitating massive transfusions. Patients frequently become coagulopathic because of the combination of dilution of platelets and clotting factors, metabolic acidosis, hypothermia, and consumption of clotting factors. Although replacement of blood loss with fresh whole blood would be ideal, this is not possible in civilian situations under current blood-banking practices. Standard therapy involves the administration of packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelets, and cryoprecipitate. Th e last of these is administered primarily to replete fi brinogen, which is commonly decreased by dilution as well as consumption. In the previous issue of Critical Care, Grottke and colleagues [1] explored the potential use of a fi brinogen concentrate instead.
Although these blood products are life-saving, they do have risks. In general, the more blood products administered, particularly PRBCs and FFP, the greater the risk for multiple organ system dysfunction and mortality [2] [3] [4] . Immunologic responses appear to play a major role.
In contrast, recent studies have suggested a benefi cial eff ect of cryoprecipitate administration. In a military population of patients receiving massive transfusions, the ratio of fi brinogen (from all blood products) to PRBCs transfused was associated with reduced mortality [5] .
Similarly, in a large database of civilians, administration of cryoprecipitate was associated with a decreased risk of multiple organ dysfunction [2] .
Fibrinogen plays a critical role in hemostasis as it promotes platelet aggregation and, when activated to form fi brin, provides the substrate for red blood cells and platelets to form strong clots. In theory, administration of exogenous fi brinogen when the endogenous levels are low could bypass missing components of the clotting cascade.
Grottke and colleagues [1] have explored the use of diff erent doses of a fi brinogen concentrate to correct the coagulopathy caused by hemodilution and to decrease bleeding in a clinically relevant animal model of trauma and hemorrhagic shock. Th is work builds upon the work of Fries and colleagues [6] , which used a larger dose of fi brinogen. Fries and colleagues found a dose-dependent improvement in standard clotting studies and thromboelasto grams (TEGs). Even with a relatively low dose, the authors found decreased bleeding and improved survival compared with controls. Th ey also found no evidence of harm from the fi brinogen administration.
Th e model used in the study by Grottke and colleagues seems to be well designed to explore questions related to trauma and coagulopathy. Th e liver injury simulates severe trauma with active bleeding, which can be quantifi ed. Coagulopathy is induced by hemodilution in a way that may be typical of the clinical situation of massive transfusion and fl uid resuscitation without replacement of plasma, fi brinogen, or platelets. Th e use of the Cell Saver® (Haemonetics, Braintree, MA, USA), which might be used clinically to salvage and re-infuse the animals' red blood cells, further simulates clinical situations. Th e only aspect of the model that is not clinically relevant is timing since the coagulopathy and fi brinogen concentrate administration precede hemorrhage. Th is limitation does not detract from the utility of the model or the importance of the fi ndings.
Th e results of this study [1] suggest that replacement of fi brinogen to a certain threshold level, perhaps as low as 70 mg/dL, is suffi cient to provide hemostasis. Since fi brino gen needs to be activated to have an eff ect, it is intriguing and important to recognize that, even with this dilutional coagulopathy, suffi cient activators seem to be present. Because of the question of activators, the authors see fi brinogen administration as adjunctive therapy to be used concomitantly with replacement of other coagulation factors.
Th ough not discussed much in the current paper, signifi cant clinical experience with the fi brinogen concentrate used in this study has been reported. Th e product is clinically approved for use in patients with congenital fi brinogen defi ciency and seems to have a good safety profi le [7] . As a result, off -label use has already been reported. Fenger-Eriksen and colleagues [8] found that use of the fi brino gen concentrate improved standard clotting studies, increased fi brinogen levels, and decreased bleed ing in patients with massive hemorrhage and decreased fi brino gen levels. Others have shown improved coagulation studies and decreased bleeding after cardiac [9], urologic [10] , and orthopedic [11] surgery.
A secondary fi nding in this study is that standard clotting studies may not represent clinical hemostatic function as these normalized while the TEG remained abnormal. Th is fi nding is in agreement with others [12, 13] and demonstrates the complexities in objectively monitoring coagulation with severe hemorrhage, hemodilution, and massive transfusions.
So where do we go from here? Grottke and colleagues [1] give us some guidance in this regard, recommending clinical studies of optimum level, need for combination therapy, timing, and patient selection. As far as the use of fi brinogen concentrates for patients with massive hemorrhage is concerned, there seem to be suffi cient preclinical and preliminary clinical data to warrant a pivotal clinical trial in patients with massive hemorrhage. Th e work by Grottke and colleagues [1], as well as by others, gives us good data for dosing of fi brinogen concen trate and for minimal fi brinogen levels to be achieved. Trauma patients in hemorrhagic shock would be an appropriate target population. It may be that focused restitution of fi brinogen levels with a fi brinogen concentrate is more effi cient and effi cacious than the use of cryoprecipitate or other blood products. Although it is unlikely that fi brinogen will be a magic bullet, it may be an excellent adjunct to blood component replacement.
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